A detailed history of Jacobs Levy Equity Management, Inc transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 440,737 shares of KRON stock, worth $427,514. This represents 0.0% of its overall portfolio holdings.

Number of Shares
440,737
Previous 59,398 642.01%
Holding current value
$427,514
Previous $77,000 609.09%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.73 - $1.38 $278,377 - $526,247
381,339 Added 642.01%
440,737 $546,000
Q1 2024

May 15, 2024

SELL
$1.02 - $1.3 $238,814 - $304,371
-234,132 Reduced 79.76%
59,398 $77,000
Q4 2023

Feb 14, 2024

BUY
$0.75 - $1.49 $182,037 - $361,646
242,716 Added 477.66%
293,530 $366,000
Q3 2023

Nov 16, 2023

SELL
$1.23 - $2.25 $5,474 - $10,014
-4,451 Reduced 8.05%
50,814 $66,000
Q2 2023

Aug 14, 2023

BUY
$1.24 - $1.92 $68,528 - $106,108
55,265 New
55,265 $95,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $55.1M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.